NCT06365437View on ClinicalTrials.gov

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 6, 2021

Primary Completion Date

December 11, 2024

Study Completion Date

December 11, 2024

Conditions
Kidney Transplantation
Interventions
BIOLOGICAL

TCD601

Investigational Product

DRUG

Tacrolimus (TAC)

Standard of Care Concomitant Immunosuppression

DRUG

Corticosteroids (CS)

Standard of Care Concomitant Immunosuppression

DRUG

Mycophenolate Mofetil (MMF)

Standard of Care Concomitant Immunosuppression

DRUG

ATG

Standard of Care induction therapy in solid organ transplantation

Trial Locations (7)

1090

University of Vienna, Vienna

14157

Karolinska University Hospital, Stockholm

20502

Skåne University Hospital, Malmo

41345

Sahlgrenska University Hospital, Gothenburg

A-6020

Innsbruck Medical University, Innsbruck

08036

Hospital Clinic de Barcelona, Barcelona

08907

Hospital Universitari de Bellvitge, Barcelona

All Listed Sponsors
lead

ITB-Med LLC

INDUSTRY